Our results suggest that combination immunotherapies for breast cancer incorporating Tamoxifen could not only enhance efficacy of targeted immunotherapy against ER+PR+ breast tumors but also expand the repertoire of “effectively targetable tumors” by immunotherapy to include tumors with otherwise negative or low target antigen expression. The gene discussed is ESR1; the disease is breast carcinoma.